Literature DB >> 22491861

Network correlates of disease severity in multiple system atrophy.

K L Poston1, C C Tang, T Eckert, V Dhawan, S Frucht, J-P Vonsattel, S Fahn, D Eidelberg.   

Abstract

OBJECTIVE: Multiple system atrophy (MSA), the most common of the atypical parkinsonian disorders, is characterized by the presence of an abnormal spatial covariance pattern in resting state metabolic brain images from patients with this disease. Nonetheless, the potential utility of this pattern as a MSA biomarker is contingent upon its specificity for this disorder and its relationship to clinical disability in individual patients.
METHODS: We used [(18)F]fluorodeoxyglucose PET to study 33 patients with MSA, 20 age- and severity-matched patients with idiopathic Parkinson disease (PD), and 15 healthy volunteers. For each subject, we computed the expression of the previously characterized metabolic covariance patterns for MSA and PD (termed MSARP and PDRP, respectively) on a prospective single-case basis. The resulting network values for the individual patients were correlated with clinical motor ratings and disease duration.
RESULTS: In the MSA group, disease-related pattern (MSARP) values were elevated relative to the control and PD groups (p < 0.001 for both comparisons). In this group, MSARP values correlated with clinical ratings of motor disability (r = 0.57, p = 0.0008) and with disease duration (r = -0.376, p = 0.03). By contrast, MSARP expression in the PD group did not differ from control values (p = 1.0). In this group, motor ratings correlated with PDRP (r = 0.60, p = 0.006) but not with MSARP values (p = 0.88).
CONCLUSIONS: MSA is associated with elevated expression of a specific disease-related metabolic pattern. Moreover, differences in the expression of this pattern in patients with MSA correlate with clinical disability. The findings suggest that the MSARP may be a useful biomarker in trials of new therapies for this disorder.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22491861      PMCID: PMC3324319          DOI: 10.1212/WNL.0b013e318250d7fd

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  28 in total

1.  Reproducibility of regional metabolic covariance patterns: comparison of four populations.

Authors:  J R Moeller; T Nakamura; M J Mentis; V Dhawan; P Spetsieres; A Antonini; J Missimer; K L Leenders; D Eidelberg
Journal:  J Nucl Med       Date:  1999-08       Impact factor: 10.057

2.  Network modulation in the treatment of Parkinson's disease.

Authors:  Kotaro Asanuma; Chengke Tang; Yilong Ma; Vijay Dhawan; Paul Mattis; Christine Edwards; Michael G Kaplitt; Andrew Feigin; David Eidelberg
Journal:  Brain       Date:  2006-07-14       Impact factor: 13.501

3.  Progression of parkinsonism in multiple system atrophy.

Authors:  Klaus Seppi; Farid Yekhlef; Anja Diem; Elisabeth Luginger Wolf; Joerg Mueller; François Tison; Niall P Quinn; Werner Poewe; Gregor K Wenning
Journal:  J Neurol       Date:  2005-01       Impact factor: 4.849

4.  FDG PET in the differential diagnosis of parkinsonian disorders.

Authors:  Thomas Eckert; Anna Barnes; Vijay Dhawan; Steve Frucht; Mark F Gordon; Andrew S Feigin; D Eidelberg
Journal:  Neuroimage       Date:  2005-04-26       Impact factor: 6.556

5.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Authors:  A J Hughes; S E Daniel; L Kilford; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

6.  Progression of multiple system atrophy (MSA): a prospective natural history study by the European MSA Study Group (EMSA SG).

Authors:  Felix Geser; Gregor K Wenning; Klaus Seppi; Michaela Stampfer-Kountchev; Christoph Scherfler; Martin Sawires; Carolin Frick; Jean-Pierre Ndayisaba; Hanno Ulmer; Maria T Pellecchia; Paolo Barone; Hee T Kim; Juzar Hooker; Niall P Quinn; Adriana Cardozo; Eduardo Tolosa; Michael Abele; Thomas Klockgether; Karen Østergaard; Erik Dupont; Nicole Schimke; Karla M Eggert; Wolfgang Oertel; Ruth Djaldetti; Werner Poewe
Journal:  Mov Disord       Date:  2006-02       Impact factor: 10.338

7.  Differential diagnosis of parkinsonism with [18F]fluorodeoxyglucose and PET.

Authors:  A Antonini; K Kazumata; A Feigin; F Mandel; V Dhawan; C Margouleff; D Eidelberg
Journal:  Mov Disord       Date:  1998-03       Impact factor: 10.338

8.  What is the accuracy of the clinical diagnosis of multiple system atrophy? A clinicopathologic study.

Authors:  I Litvan; C G Goetz; J Jankovic; G K Wenning; V Booth; J J Bartko; A McKee; K Jellinger; E C Lai; J P Brandel; M Verny; K R Chaudhuri; R K Pearce; Y Agid
Journal:  Arch Neurol       Date:  1997-08

9.  Striatal hypometabolism distinguishes striatonigral degeneration from Parkinson's disease.

Authors:  D Eidelberg; S Takikawa; J R Moeller; V Dhawan; K Redington; T Chaly; W Robeson; J R Dahl; D Margouleff; E Fazzini
Journal:  Ann Neurol       Date:  1993-05       Impact factor: 10.422

10.  The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations.

Authors:  Tetsutaro Ozawa; Dominic Paviour; Niall P Quinn; Keith A Josephs; Hardev Sangha; Linda Kilford; Daniel G Healy; Nick W Wood; Andrew J Lees; Janice L Holton; Tamas Revesz
Journal:  Brain       Date:  2004-10-27       Impact factor: 13.501

View more
  22 in total

1.  Abnormal metabolic network activity in REM sleep behavior disorder.

Authors:  Florian Holtbernd; Jean-François Gagnon; Ron B Postuma; Yilong Ma; Chris C Tang; Andrew Feigin; Vijay Dhawan; Mélanie Vendette; Jean-Paul Soucy; David Eidelberg; Jacques Montplaisir
Journal:  Neurology       Date:  2014-01-22       Impact factor: 9.910

2.  Correlations between dopaminergic dysfunction and abnormal metabolic network activity in REM sleep behavior disorder.

Authors:  Zhemin Huang; Chengfeng Jiang; Ling Li; Qian Xu; Jingjie Ge; Ming Li; Yihui Guan; Jianjun Wu; Jian Wang; Chuantao Zuo; Huan Yu; Ping Wu
Journal:  J Cereb Blood Flow Metab       Date:  2019-02-10       Impact factor: 6.200

3.  A systematic review of lessons learned from PET molecular imaging research in atypical parkinsonism.

Authors:  Jean-Claude Baron
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-12-15       Impact factor: 9.236

Review 4.  Brain network markers of abnormal cerebral glucose metabolism and blood flow in Parkinson's disease.

Authors:  Shichun Peng; David Eidelberg; Yilong Ma
Journal:  Neurosci Bull       Date:  2014-09-28       Impact factor: 5.203

5.  Metabolic network expression in parkinsonism: Clinical and dopaminergic correlations.

Authors:  Ji Hyun Ko; Chong Sik Lee; David Eidelberg
Journal:  J Cereb Blood Flow Metab       Date:  2016-07-21       Impact factor: 6.200

6.  Identification of disease-related spatial covariance patterns using neuroimaging data.

Authors:  Phoebe Spetsieris; Yilong Ma; Shichun Peng; Ji Hyun Ko; Vijay Dhawan; Chris C Tang; David Eidelberg
Journal:  J Vis Exp       Date:  2013-06-26       Impact factor: 1.355

Review 7.  Functional brain networks in movement disorders: recent advances.

Authors:  Florian Holtbernd; David Eidelberg
Journal:  Curr Opin Neurol       Date:  2012-08       Impact factor: 5.710

Review 8.  PET Imaging in Movement Disorders.

Authors:  Baijayanta Maiti; Joel S Perlmutter
Journal:  Semin Nucl Med       Date:  2018-08-16       Impact factor: 4.446

Review 9.  The utility of neuroimaging in the differential diagnosis of parkinsonian syndromes.

Authors:  Florian Holtbernd; David Eidelberg
Journal:  Semin Neurol       Date:  2014-06-25       Impact factor: 3.420

Review 10.  Neuroimaging of Parkinson's disease: Expanding views.

Authors:  Carol P Weingarten; Mark H Sundman; Patrick Hickey; Nan-kuei Chen
Journal:  Neurosci Biobehav Rev       Date:  2015-09-26       Impact factor: 8.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.